Kemp Dolliver
Stock Analyst at Brookline Capital
(0)
# 4483
Out of 5,240 analysts
24
Total ratings
25.00%
Success rate
-13.55%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Y-mAbs Therapeutics | Initiates Coverage On: Buy | 17 | 6.33 | 168.56% | 1 | Dec 5, 2024 | |
Eyenovia | Downgrades: Hold | n/a | n/a | n/a | 2 | Nov 15, 2024 | |
Verrica Pharmaceutic... | Downgrades: Hold | n/a | n/a | n/a | 2 | Oct 2, 2024 | |
Oncternal Therapeuti... | Downgrades: Hold | n/a | n/a | n/a | 3 | Sep 12, 2024 | |
iBio | Initiates Coverage On: Buy | 4 | 2.71 | 32.84% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 36 | 3.33 | 981.08% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 32 | 2.17 | 1347% | 1 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 27 13 | n/a | n/a | 1 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 100 | 92.63 | 7.96% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 57 | 1.59 | 3484.91% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 5 | 1.76 | 155.68% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 25 | 2.45 | 920.41% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 19 | 15.81 | 18.6% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 8 | 1.16 | 589.66% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 6 | 1.23 | 359.35% | 1 | Feb 2, 2022 |